Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint

(2011) Sara A. Hurvitz   CANCER TREATMENT REVIEWS

Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis

(2011) Mohammad H Forouzanfar et al.   LANCET

In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling

(2010) S. de Haij et al.   CANCER RESEARCH

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Antibodies to TWEAK Receptor Inhibit Human Tumor Growth through Dual Mechanisms

(2010) P. A. Culp et al.   CLINICAL CANCER RESEARCH

FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK

(2009) Emmanuel Chorianopoulos et al.   BASIC RESEARCH IN CARDIOLOGY

TWEAK promotes ovarian cancer cell metastasis via NF-κB pathway activation and VEGF expression

(2009) Lan Dai et al.   CANCER LETTERS

What’s positive about ‘triple-negative’ breast cancer?

(2009) Sara A Hurvitz et al.   Future Oncology

Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes

(2009) X. Hu et al.   MOLECULAR CANCER RESEARCH

The Fibroblast Growth Factor-Inducible 14 Receptor Is Highly Expressed in HER2-Positive Breast Tumors and Regulates Breast Cancer Cell Invasive Capacity

(2008) A. L. Willis et al.   MOLECULAR CANCER RESEARCH

The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting

(2008) Jeffrey A. Winkles   NATURE REVIEWS DRUG DISCOVERY